# Outlook Therapeutics, Inc. (OTLK)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001649989 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001649989))
- Full page: https://inspectstocks.com/stocks/otlk
- Data as of: price 2026-09-29; newest filing used 2026-08-18; latest fiscal period ended 2026-06-30

## Grade

**F+** on the balance-sheet rubric used for lenders, 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$61.1M |  |
| Earnings growing overall | failed | -$61.1M | -$60.3M |
| Earnings growing recently | passed | -$61.1M | -$62.4M |
| Earns well on its assets | failed | -233.4% |  |
| Book value per share growing | failed | -$0.93 | $0.00 |

Business quality (the + / − mark): 6 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 5,253.5% |  |
| Healthy profit margin | passed | 5,253.5% |  |
| Strong operating margin | passed | 4,781.8% |  |
| Good return on equity | passed | 189.9% |  |
| Debt under control | passed | -0.94 |  |
| Turns sales into cash | passed | 2,812.9% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | -$1.2M |
| Net income, trailing twelve months | -$61.1M |
| Net margin | 5,253.5% |
| Operating margin | 4,781.8% |
| Return on equity | 189.9% |
| Debt to equity | -0.94 |
| Diluted EPS, trailing twelve months | -$0.77 |
| Share price | $0.63 |
| Market value | $58.4M |

## More on this company

- [Overview](https://inspectstocks.com/stocks/otlk)
- [Financial statements](https://inspectstocks.com/stocks/otlk/financials)
- [Competitors](https://inspectstocks.com/stocks/otlk/peers)
- [Earnings](https://inspectstocks.com/stocks/otlk/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.